title: What do we do with chronic lymphocytic leukemia with 17p deletion?
abstract: Chronic lymphocytic leukemia (CLL) with 17p deletion or mutations of the TP53 gene has a very poor outcome. Optimal treatment of these patients remains a major clinical challenge, and disagreement on the optimal treatment approach exists. Conventional chemo-immunotherapy with rituximab in combination with purine analogues yields lower response-rates and less satisfactory results than for CLL patients with intact p53. Allogeneic stem cell transplantation may allow long-term remissions in this challenging group of patients. In this review, we will discuss current treatment options as well as experimental approaches in clinical trials for CLL patients with deleted or mutated TP53. Particular emphasis will be placed on novel agents with the potential to change clinical practice and future perspectives for the management of these "highest risk" patients.
authors.affiliation: Department of Translational Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, 69120, Heidelberg, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Sellner
authors.forename: S
authors.initials: S
authors.lastname: Denzinger
authors.forename: S
authors.initials: S
authors.lastname: Dietrich
authors.forename: H
authors.initials: H
authors.lastname: Glimm
authors.forename: O
authors.initials: O
authors.lastname: Merkel
authors.forename: P
authors.initials: P
authors.lastname: Dreger
authors.forename: T
authors.initials: T
authors.lastname: Zenz
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics*; D016158:Genes, p53; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics* / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D017384:Sequence Deletion; D033581:Stem Cell Transplantation; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D016159:Tumor Suppressor Protein p53